Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jun 2027 → Oct 31, 2027
See other at-risk trials from Pharmacosmos A/S

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Pharmacosmos A/S to Pharmacosmos A/S Show 4 more changesShow less
    • Start date: Jun 30, 2026 to Sep 2026
    • Primary and study completion pushed from Jun 2027 to Oct 31, 2027
    • Eligibility criteria expanded, about 8 words
    • Site contact updated
  2. Recruitment opened
    • Start date: Mar 31, 2026 to Jun 30, 2026
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
Trial Details
NCT Number NCT07473128
Lead Sponsor Pharmacosmos A/S
Conditions
(from sponsor)		 Limited Stage Small Cell Lung Cancer
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov